EliteImmune focuses on creating antibody-based drugs for targeted therapy and prophylaxis of infectious diseases. Powered by our proprietary CellProbe™ and CellSeq™ platforms, we pinpoint naturally occurring leads by high-resolution and high-throughput screening of B cell repertoires from elite donors. We have a robust pipeline of rare antibodies with superior selectivity, affinity, and therapeutic efficacy to combat deadly infectious diseases.
Eliteimmune is poised to enter the immuno-oncology and aging space with novel antibodies targeting neoantigens. We seek to establish partnerships with global pharmaceutical and biotech companies for future licensing and co-development.
We designed a state-of-the-art laboratory dedicated to accelerating research.
Eliteimmune’s cutting-edge laboratory is situated in Gaithersburg, Maryland, the heart of the BioHealth Capital Region. This region consists of over 800 life science companies and 70 federal laboratories. In 2016, the region is ranked 4th in Top Biopharma Clusters in the country by Genetic Engineering News.
We are expanding our research
capacity and infrastructure in China
Our second headquarter is located in the Tianjin International Joint Academy of Biomedicine, the core and landmark of Bio-Med Zone of Binhai New Area, Tianjin, China. The headquarter in China is equal in stature to our home base in the US. EliteImmune is committed to delivering the most innovative and effective therapeutics from our dual R&D engines advancing the quality of human health.